Bruker (NASDAQ:BRKR) Shares Gap Down – What’s Next?

Bruker Corporation (NASDAQ:BRKR)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $64.31, but opened at $54.07. Bruker shares last traded at $52.87, with a volume of 1,433,303 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BRKR shares. Zacks Research upgraded shares of Bruker from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Barclays boosted their price objective on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Wolfe Research started coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Finally, Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Stock Performance

The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.72. The company has a fifty day moving average price of $58.67 and a two-hundred day moving average price of $46.73. The company has a market capitalization of $7.99 billion, a P/E ratio of -74.96, a PEG ratio of 1.61 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same period in the previous year, the business earned $0.32 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is -83.33%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans grew its holdings in shares of Bruker by 561.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of Bruker by 202.7% during the fourth quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock valued at $1,946,000 after purchasing an additional 27,659 shares in the last quarter. Franklin Resources Inc. lifted its position in Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the period. Fifth Third Bancorp increased its stake in shares of Bruker by 4,058.3% in the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock worth $2,064,000 after acquiring an additional 55,761 shares in the last quarter. Finally, VELA Investment Management LLC increased its stake in shares of Bruker by 51.0% during the fourth quarter. VELA Investment Management LLC now owns 102,700 shares of the medical research company’s stock valued at $4,838,000 after purchasing an additional 34,700 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.